Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial
Sleep Medicine · 2026-12 · 148 · 109260
DOI: 10.1016/j.sleep.2026.109260 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sleep Medicine, 2026-12. Verfasst von Naohisa Uchimura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Orexin Receptor Antagonists, Triazoles. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taisho Toyama Pharmaceutical Company.
Themen: Schlaf
Abstract (Originalsprache)
STUDY OBJECTIVES: This study aimed to evaluate the long-term safety and efficacy of vornorexant, a novel dual orexin receptor antagonist, in Japanese patients with insomnia. METHODS: This multicenter, randomized, open-label trial consisted of a 1-week screening period, an initial 26-week treatment period followed by an optional 26-week extension (for a total of up to 52 weeks), and a 1-week single-blind placebo run-out period. Patients received vornorexant 5 mg (VOR5) or vornorexant 10 mg (VOR10) during the treatment period(s). Safety assessments included adverse events, withdrawal symptoms, and rebound insomnia. Efficacy for sleep onset and maintenance was evaluated using patient-reported sleep diaries. Subgroup analyses by age and sex were conducted. RESULTS: A total of 371 patients were randomized; 38 discontinued during the initial period and 8 during the extension. The most common adverse events were nasopharyngitis (10.9% and 8.2%) and somnolence (5.4% and 12.0%) in VOR5 and VOR10, respectively. No withdrawal symptoms and rebound insomnia of clinical concern were detected. Regarding efficacy, mean change from baseline (CFB) in subjective sleep latency were -31.2 and -38.9 min at week 26 and -31.8 and -44.0 min at week 52 for VOR5 and VOR10, respectively. For sleep maintenance, mean CFB in subjective sleep efficiency were 14.07% and 17.63% at week 26 and 15.56% and 20.40% at week 52, respectively. Changes were generally similar across age and sex subgroups; however, psychiatric comorbidity subgroup analyses were underpowered. CONCLUSIONS: Long-term vornorexant treatment was well tolerated, and improvements in sleep onset and sleep maintenance were observed for up to 52 weeks in Japanese patients with insomnia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan.
- Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan. Electronic address: d-kanbe@taisho.co.jp.
- Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
- Tokyoadachi Hospital, Tokyo, Japan; Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan.
Förderung
- Taisho Toyama Pharmaceutical Company
Zitieren
APA
Uchimura, N., Kambe, D., Hasegawa, S., Imadera, Y., Yamasaki, H., & Uchiyama, M. (2026). Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial. Sleep Medicine, 148, 109260. https://doi.org/10.1016/j.sleep.2026.109260
Vancouver
Uchimura N, Kambe D, Hasegawa S, Imadera Y, Yamasaki H, Uchiyama M. Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial. Sleep Medicine. 2026;148:109260. doi:10.1016/j.sleep.2026.109260
BibTeX
@article{Uchimura2026,
author = {Uchimura, Naohisa and Kambe, Daiji and Hasegawa, Sayaka and Imadera, Yumiko and Yamasaki, Hironori and Uchiyama, Makoto},
title = {Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial},
journal = {Sleep Medicine},
year = {2026},
volume = {148},
pages = {109260},
doi = {10.1016/j.sleep.2026.109260}
}
EUVIMED